Cargando…

Crystal Structure of the FLT3 Kinase Domain Bound to the Inhibitor Quizartinib (AC220)

More than 30% of acute myeloid leukemia (AML) patients possess activating mutations in the receptor tyrosine kinase FMS-like tyrosine kinase 3 or FLT3. A small-molecule inhibitor of FLT3 (known as quizartinib or AC220) that is currently in clinical trials appears promising for the treatment of AML....

Descripción completa

Detalles Bibliográficos
Autores principales:	Zorn, Julie A., Wang, Qi, Fujimura, Eric, Barros, Tiago, Kuriyan, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383440/ https://www.ncbi.nlm.nih.gov/pubmed/25837374 http://dx.doi.org/10.1371/journal.pone.0121177

Ejemplares similares

Quizartinib (AC220): a promising option for acute myeloid leukemia
por: Zhou, Fang, et al.
Publicado: (2019)

Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms
por: Kampa-Schittenhelm, Kerstin Maria, et al.
Publicado: (2013)

Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: In vitro and in vivo studies
por: Li, Jun, et al.
Publicado: (2017)

Overcoming AC220 resistance of FLT3-ITD by SAR302503
por: Kesarwani, M, et al.
Publicado: (2013)

Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms
por: Patel, Ami B., et al.
Publicado: (2020)

The Combined Treatment With the FLT3-Inhibitor AC220 and the Complex I Inhibitor IACS-010759 Synergistically Depletes Wt- and FLT3-Mutated Acute Myeloid Leukemia Cells
por: Lu, Xiyuan, et al.
Publicado: (2021)

Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite
por: Li, Jianke, et al.
Publicado: (2019)

Repurposing of Ibrutinib and Quizartinib as potent inhibitors of necroptosis
por: Huang, Fangmin, et al.
Publicado: (2023)

The FLT3 Inhibitor Quizartinib Inhibits ABCG2 at Pharmacologically Relevant Concentrations, with Implications for Both Chemosensitization and Adverse Drug Interactions
por: Bhullar, Jasjeet, et al.
Publicado: (2013)

Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial
por: Papadopoulos, Kyriakos P., et al.
Publicado: (2018)

Internal Tandem Duplication in FLT3 Attenuates Proliferation and Regulates Resistance to the FLT3 Inhibitor AC220 by Modulating p21(Cdkn1a) and Pbx1 in Hematopoietic Cells
por: Abe, Mariko, et al.
Publicado: (2016)

Effect of Food on the Pharmacokinetics of Quizartinib
por: Li, Jianke, et al.
Publicado: (2020)

Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports
por: Martínez-Cuadrón, David, et al.
Publicado: (2020)

P531: MIDOSTAURIN PLUS 7 + 3 OR QUIZARTINIB PLUS 7 + 3 IN FLT3-ITD MUTATED AML
por: Tormo, Mar, et al.
Publicado: (2023)

Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells
por: Aikawa, Tomoya, et al.
Publicado: (2020)

Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date
por: Fletcher, Luke, et al.
Publicado: (2020)

Sleeping through the storm: Preventing myelosuppression with quizartinib
por: Taylor, Samuel J., et al.
Publicado: (2017)

Crystal structure of the kinase domain of a receptor tyrosine kinase from a choanoflagellate, Monosiga brevicollis
por: Bajaj, Teena, et al.
Publicado: (2023)

S137: IMPACT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN FIRST COMPLETE REMISSION PLUS FLT3 INHIBITION WITH QUIZARTINIB IN ACUTE MYELOID LEUKEMIA WITH FLT3-ITD: RESULTS FROM QUANTUM-FIRST
por: Schlenk, Richard, et al.
Publicado: (2023)

Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL
por: Dumas, Pierre-Yves, et al.
Publicado: (2019)

Synergistic effect of a novel autophagy inhibitor and Quizartinib enhances cancer cell death
por: Ouchida, Amanda Tomie, et al.
Publicado: (2018)

Crystal Structures of Two Aminoglycoside Kinases Bound with a Eukaryotic Protein Kinase Inhibitor
por: Fong, Desiree H., et al.
Publicado: (2011)

Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD
por: Jaramillo, Sonia, et al.
Publicado: (2023)

Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia
por: Green, Alexa S., et al.
Publicado: (2015)

A Review of FLT3 Kinase Inhibitors in AML
por: Negotei, Cristina, et al.
Publicado: (2023)

CompTIA A+: exams A+ essentials (220-601), 220-602, 220-603, 220-604
por: Brooks, Charles J, et al.
Publicado: (2008)

Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia
por: Kang, Dongwoo, et al.
Publicado: (2021)

Combating drug resistance in acute myeloid leukaemia by drug rotations: the effects of quizartinib and pexidartinib
por: Yang, Jingmei, et al.
Publicado: (2021)

CCL5 mediates target‐kinase independent resistance to FLT3 inhibitors in FLT3‐ITD‐positive AML
por: Waldeck, Silvia, et al.
Publicado: (2020)

CompTIA A+ 220-901 and 220-902
por: Prowse, David L
Publicado: (2016)

CompTIA A+ 220-801 and 220-802
por: Prowse, David L
Publicado: (2013)

CompTIA A+: 220-701 and 220-702
por: Prowse, David L
Publicado: (2011)

CompTIA A+ practice questions: essentials, exams 220-602, 220-603, 220-604
por: Brooks, Charles J
Publicado: (2008)

S131: A RANDOMISED ASSESSMENT OF THE SEQUENTIAL ADDITION OF THE KINASE INHIBITOR QUIZARTINIB TO INTENSIVE CHEMOTHERAPY IN OLDER ACUTE MYELOID LEUKAEMIA (AML) PATIENTS: RESULTS FROM THE NCRI AML18 TRIAL
por: Knapper, Steven, et al.
Publicado: (2023)

Crystal structures of the S6K1 kinase domain in complexes with inhibitors
por: Niwa, Hideaki, et al.
Publicado: (2014)

FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review
por: Loschi, Michael, et al.
Publicado: (2021)

Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid Leukemia
por: Kang, Dongwoo, et al.
Publicado: (2020)

S130: PRELIMINARY RESULTS OF QUIWI: A DOUBLE BLINDED, RANDOMIZED CLINICAL TRIAL COMPARING STANDARD CHEMOTHERAPY PLUS QUIZARTINIB VERSUS PLACEBO IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3-ITD WILD-TYPE AML
por: Montesinos, Pau, et al.
Publicado: (2023)

Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
por: James, Angela Joubert, et al.
Publicado: (2020)

Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase
por: Weisberg, Ellen L., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hiv56utumeg8eo54hfm3kupohc